Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

@article{Kaplan2011HyperactivationOM,
  title={Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells},
  author={F. M. Kaplan and Y. Shao and M. M. Mayberry and A. Aplin},
  journal={Oncogene},
  year={2011},
  volume={30},
  pages={366-371}
}
  • F. M. Kaplan, Y. Shao, +1 author A. Aplin
  • Published 2011
  • Biology, Medicine
  • Oncogene
    • Activating mutations in B-RAF and N-RAS occur in ∼60 and ∼15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK–ERK1/2 pathway. Thus, B-RAFV600E is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720… CONTINUE READING
    View on Nature
    nature.com
    105 Citations
    Highly Influencial Citations
    7
    Background Citations
    39
    Methods Citations
    1
    Results Citations
    1

    Figures and Topics from this paper

    Figures

    Explore Further: Topics Discussed in This Paper

    105 Citations
    Citation Type

    Citation Type

    Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells
    • 67
    The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
    • 306
    • PDF
    SHOC2 and CRAF Mediate ERK1/2 Reactivation in Mutant NRAS-mediated Resistance to RAF Inhibitor*
    • 46
    • PDF
    Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
    • 47
    • PDF
    MEK targeting in N-RAS mutated metastatic melanoma
    • 40
    P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
    • 27
    • PDF
    Inhibition of mutant BRAF splice variant signaling by next‐generation, selective RAF inhibitors
    • 32
    Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
    • 23
    The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
    • 18
    • Highly Influenced
    • PDF
    TheActivation ofMAPK inMelanomaCells Resistant toBRAF Inhibition Promotes PD-L 1 Expression That Is Reversible by MEK and PI 3 K Inhibition
    • 10
    • PDF

    References

    SHOWING 1-10 OF 27 REFERENCES
    B-RAF is a therapeutic target in melanoma
    • 432
    • PDF
    PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
    • 288
    • Highly Influential
    • PDF
    Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
    • 2,254
    • PDF
    B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis
    • 67
    • PDF
    RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • 1,279
    • PDF
    Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
    • 114
    • PDF
    RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
    • 1,425
    • PDF
    BRAF mutation predicts sensitivity to MEK inhibition
    • 1,237
    • PDF
    Mutant B-RAF mediates resistance to anoikis via Bad and Bim
    • 101
    • PDF
    Paradoxical activation of Raf by a novel Raf inhibitor.
    • 232
    • PDF